Novo Nordisk A/S vs Realty Income Corp — how do they compare? Novo Nordisk A/S trades at $45.93 (market cap $207.85B), while Realty Income Corp trades at $61.94 (market cap $58.56B). The key difference: Novo Nordisk A/S is far larger — about 3.5× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (5.25%). Which is the better fit depends on your goals.
| NVO | O | |
|---|---|---|
Market Cap | $207.85B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $63.98 | $67.56 |
52-Week Low | $35.29 | $55.93 |
Enterprise Value | $222.55B | $89.19B |
Dividend Yield | 3.81% | 5.25% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →